All In Biotech

Drug Trial Radar · NCT07875426

A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria

A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 Injection in Patients With Chronic Spontaneous Urticaria

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

201

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Jan 8, 2029

Study completion Feb 5, 2029

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 injection in patients with chronic spontaneous urticaria (CSU) receiving background treatment with H1-antihistamines (H1-AHs).

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • AK139Biological

    AK139 administered subcutaneously

  • PlaceboBiological

    Placebo administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 7-Day Urticaria Activity Score (UAS7) .Time frame: Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.